Skip to content

Illumina ILMN United States and Canada — Total Revenue

Other geography segments

Europe, Middle East, Africa and Latin America
$356M
Asia-Pacific
$93M

Similar metrics at other companies

Pacific Biosciences of California logo
PACBUnited States — Total Revenue
$17.43M-7.4%
Gartner logo
ITUnited States and Canada — Total revenues
$924.31M-7.0%
Xperi logo
XPERUS And Canada — Revenue
$50.89M+2.4%
Avient logo
AVNTUnited States and Canada — Total Sales
$327.33M-2.0%
Inseego Corp. logo
INSGUnited States and Canada — Total revenues
$34.23M+8.3%
JBT Marel Corporation logo
JBTMU.S. and Canada — Revenue
$356M+2.9%

Other financials

Income statement

See full
Revenue$1.1B+4.8%
Gross profit$721.0M+5.6%
Operating income$209.0M+27.4%
Net income$134.0M+2.3%
EPS (diluted)$0.87+6.1%

Balance sheet

See full
Cash & equivalents$1.1B-2.2%
Total debt$2.0B-3.0%
Total equity$2.7B+13.0%
Total assets$6.6B+6.1%

Cash flow

See full
Operating cash flow$289.0M+20.4%
CapEx$38.0M+18.8%
Free cash flow$251.0M+20.7%

Valuation

See full
Market cap$26.6B+91.5%
Enterprise value$27.56B+83.6%
P/E31.2×+20.1×
P/S6.1×+2.8×

Profitability

See full
Gross margin66.2%-0.1pp
Operating margin19.4%
Net margin19.4%+12.7pp
FCF margin22.2%+2.0pp

Returns & leverage

See full
Return on equity33.8%+23.9pp
Debt / equity0.8×-0.1×
Current ratio1.7×-0.1×

Where this comes from

Reported directly by Illumina in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Illumina’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Illumina's united states and canada — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Illumina's united states and canada — total revenue?
Illumina (ILMN) reported united states and canada — total revenue of $590M in Q1 2026.
What does united states and canada — total revenue mean?
This metric represents the total net revenue generated from the sale of sequencing instruments, consumables, and related services within the North American market, specifically the United States and Canada. It serves as a primary indicator of regional market penetration and demand for genomic sequencing technologies in clinical and life science research sectors. As a core geographic segment, it reflects the company's ability to capitalize on the largest global market for high-throughput genetic analysis.